3-(1H-Indol-2-YL)-N-isopropyl-1H-pyrazole-4-carboxamide | 827318-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(1H-Indol-2-YL)-N-isopropyl-1H-pyrazole-4-carboxamide
• 英文别名: 5-(1H-indol-2-yl)-N-propan-2-yl-1H-pyrazole-4-carboxamide
• CAS: 827318-51-4
• 化学式: C₁₅H₁₆N₄O
• 分子量: 268.31
• InChiKey: CDHCLSCFCOKEKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  73.6
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2020150545A1

  公开（公告）日：2020-07-23

  Pyrazole compounds (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a pyrazole compounds, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  本发明涉及用于治疗各种疾病和病理的吡唑化合物（I）。更具体地，本公开涉及使用吡唑化合物，在治疗通过激活Wnt途径信号特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎）中，调节由Wnt途径信号介导的细胞事件，以及与DYRK1A过度表达相关的神经症状/疾病。
• PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1648884A2

  公开（公告）日：2006-04-26
• [EN] PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES DE PYRAZOLYL-INDOLE ACTIFS EN TANT QU'INHIBITEURS DE KINASE, PROCEDE DE PREPARATION CORRESPONDANT ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2005005414A2

  公开（公告）日：2005-01-20

  Pyrazolyl-indole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.